Abstract:Inhibition of glycolysis process has been an attractive approach for cancer treatment due to the evidence that tumor cells are more dependent on glycolysis rather than oxidative phosphorylation pathway. Preliminary evidence shows that inhibition of phosphoglycerate kinase 1 (PGK1) kinase activity would reverse the Warburg effect and make tumor cells lose the metabolic advantage for fueling the proliferation through restoration of the pyruvate dehydrogenase (PDH) activity and subsequently promotion of pyruvic acid to enter the Krebs cycle in glioma. However, due to the lack of small molecule inhibitors of PGK1 kinase activity to treat glioma, whether PGK1 could be a therapeutic target of glioma has not been pharmacologically verified yet. In this study we developed a high-throughput screening and discovered that NG52, previously known as a yeast cell cycle-regulating kinase inhibitor, could inhibit the kinase activity of PGK1 (the IC50 = 2.5 ± 0.2 μM). We showed that NG52 dose-dependently inhibited the proliferation of glioma U87 and U251 cell lines with IC50 values of 7.8 ± 1.1 and 5.2 ± 0.2 μM, respectively, meanwhile it potently inhibited the proliferation of primary glioma cells. We further revealed that NG52 (12.5–50 μM) effectively inhibited the phosphorylation of PDHK1 at Thr338 site and the phosphorylation of PDH at Ser293 site in U87 and U251 cells, resulting in more pyruvic acid entering the Krebs cycle with increased production of ATP and ROS. Therefore, NG52 could reverse the Warburg effect by inhibiting PGK1 kinase activity, and switched cellular glucose metabolism from anaerobic mode to aerobic mode. In nude mice bearing patient-derived glioma xenograft, oral administration of NG52 (50, 100, 150 mg· kg−1·d−1, for 13 days) dose-dependently suppressed the growth of glioma xenograft. Together, our results demonstrate that targeting PGK1 kinase activity might be a potential strategy for glioma treatment.

Application of GSK503 in preparing drug for treating RB (Retinoblastoma)

EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

Application of EZH2 (enhancer of zeste homolog 2) inhibitor compounds in preparation of drugs for treating eye melanoma

The Use of rAAV2-<i>RB1</i>-Mediated Gene Therapy in Retinoblastoma

Exth-07. Unraveling The Role Of Shh Signaling Pathway In Retinoblastoma

Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle

An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatform for synergistic therapy targeting MDM2 for retinoblastoma

Advance in the chemotherapy resistance of retinoblastoma

ETMR-25. UNRAVELING THE ROLE OF SHH SIGNALING PATHWAY IN RETINOBLASTOMA

Resurrecting p53 by an Artificial Nano‐Protein for Potent Photodynamic Retinoblastoma Therapy

IGF2BP3-dependent N6-methyladenosine modification of USP49 promotes carboplatin resistance in retinoblastoma by enhancing autophagy via regulating the stabilization of SIRT1

Genetic characteristics and clinical screening and treatment of retinoblastoma

[Pay Attention to the Application of the International Intraocular Retinoblastoma Classification and Sequential Multiple Modality Treatment].

Identification of Rocaglate Acyl Sulfamides as Selective Inhibitors of Glioblastoma Stem Cells

Focused cancer pathway analysis revealed unique therapeutic targets in retinoblastoma

A Novel Potent CDK4/6 Inhibitor BPI-16350 in Preclinical Cancer Models

Dddr-14. Improved Anti-Glioblastoma Efficacy By Brg399, A Novel Oral Microtubule Binding Agent

Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3 Inhibitors for the Treatment of Acute Promyelocytic Leukemia

Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52

Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia